Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4(+) T cell activation and HIV-1 latency reversal

A proposed strategy to cure HIV uses latency-reversing agents (LRAs) to reactivate latent proviruses for purging HIV reservoirs. A variety of LRAs have been identified, but none has yet proven effective in reducing the reservoir size in vivo. Nanocarriers could address some major challenges by impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Shijie, Slack, Sarah D., Levy, Claire N., Hughes, Sean M., Jiang, Yonghou, Yogodzinski, Christopher, Roychoudhury, Pavitra, Jerome, Keith R., Schiffer, Joshua T., Hladik, Florian, Woodrow, Kim A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436934/
https://www.ncbi.nlm.nih.gov/pubmed/30944862
http://dx.doi.org/10.1126/sciadv.aav6322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436934/
https://www.ncbi.nlm.nih.gov/pubmed/30944862
http://dx.doi.org/10.1126/sciadv.aav6322

Ejemplares similares